Drugs / Humulin R U-500
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07341373 | Feb → Sep 2026 overdue | type 1 diabetes mellitus | Portal Diabetes, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05413863 | May → Dec 2022 | — | Biocon Limited | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT02324309 Comparator | May → Nov 2014 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 1/2 | NCT02212951 Comparator | May → Jul 2014 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humulin R U-500 | “A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin® R U-500 and Humalog® Mix75/25™ in Subjects With Type 2...” NCT02324309 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast” NCT02212951 ↗ |